Research programme: anti-somatostatin vaccines - Braasch Biotech

Drug Profile

Research programme: anti-somatostatin vaccines - Braasch Biotech

Alternative Names: JH17; JH18; Somatovac®

Latest Information Update: 28 May 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Braasch Biotech
  • Class Peptide vaccines
  • Mechanism of Action Immunomodulators; Somatostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Obesity
  • Research Somatotropin deficiency; Type 2 diabetes mellitus

Most Recent Events

  • 30 Apr 2013 Preclinical development in Obesity is ongoing in USA
  • 31 Aug 2009 Early research in Somatotropin deficiency (in children) in USA (Parenteral)
  • 31 Aug 2009 Early research in Type-2 diabetes mellitus in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top